COMPANY RESEARCHGan & Lee Pharmaceuticals Co., Ltd.
Gan & Lee Pharmaceuticals is a listed Chinese pharmaceutical company specializing in medicines for diabetes and other metabolic diseases. It has extensive experience developing and manufacturing insulin products, including insulin analogues, and has expanded research into additional therapeutic areas. Its official corporate website displays the Shanghai stock code and describes its research, manufacturing and international business. The company's activities include both commercial pharmaceutical operations and continued drug development. Its research and manufacturing are anchored in therapies for diabetes and metabolic disorders.
Company at a glance
Corporate information
- Company entity
- Gan & Lee Pharmaceuticals Co., Ltd.
- Headquarters / principal office
- China
- Founded
- Not verified
- Ownership / capital status
- Publicly tradedPublicly listed
- Official corporate reference
- https://www.ganlee.com/
- LinkedIn company page
- Independent company page not verified
Profile review: 2026-11-08 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Listed issuer and R&D focus
SSE: 603087
insulin analogs · peptide therapeutics
diabetes · obesity · metabolic disease
Last independently verified:
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
Gan & Lee Pharmaceuticals is a listed Chinese pharmaceutical company specializing in medicines for diabetes and other metabolic diseases. It has extensive experience developing and manufacturing insulin products, including insulin analogues, and has expanded research into additional therapeutic areas. Its official corporate website displays the Shanghai stock code and describes its research, manufacturing and international business. The company's activities include both commercial pharmaceutical operations and continued drug development. Its research and manufacturing are anchored in therapies for diabetes and metabolic disorders.
Business, technology & evidence
- SecuritiesSSE: 603087
Individual program detail is not recorded. Consult the original sources below.
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Showing 0 / 0 related items
No cataloged update explicitly mentions this company.
Same-field reading (not company-specific)
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinSources & open questions
- Official issuer and R&D disclosure · Gan & Lee Pharmaceuticals Co., Ltd. ↗Gan & Lee Pharmaceuticals Co., Ltd. ·
- Official issuer and R&D disclosure · Gan & Lee Pharmaceuticals Co., Ltd. ↗Gan & Lee Pharmaceuticals Co., Ltd. ·
Inclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.